Wave Life Sciences Slips as Obesity Data Fails to Convince

Wave Life Sciences (NASDAQ:WVE) shares are trading near historic lows after two Wall Street firms cut their price targets following updated Phase 1 INLIGHT trial data for WVE-007, the company’s obesity candidate.

The stock fell nearly 50% on March 26, closing at $6.20 — its lowest level in over a year — as investors concluded the data fell short of what would be needed to establish WVE-007 as a standalone obesity therapy. So far this year, shares of WVE are down more than 60%

The Analyst Case

BofA lowered its price target to $21 from $38 while maintaining a Buy rating, arguing that more evidence is needed to convince investors of WVE-007’s potential — particularly as a monotherapy. The firm still sees opportunity in higher BMI patients and in combination with incretins or as a post-incretin maintenance treatment.

Wells Fargo cut its target to $13 from $27, keeping an Overweight rating, but flagged reduced conviction that Activin E knockdown in the liver will reliably drive meaningful fat loss, citing the 400mg cohort data specifically. The firm’s concern centers on whether the mechanism translates into clinically relevant weight reduction at the doses tested so far.

What the Data Actually Showed

The INLIGHT interim readout reported a 14.3% placebo-adjusted reduction in visceral fat six months after a single dose, alongside preservation of lean muscle mass — a differentiated profile compared to GLP-1 therapies that often reduce muscle alongside fat. Earlier cohort data showed up to 85% mean Activin E reduction at the 400mg dose, yet the market’s reaction suggests target suppression of the biomarker did not translate into the fat-loss magnitude investors were pricing in.

A complicating factor: the Phase 1 population included individuals with lower BMI than typical obesity studies, meaning the monotherapy signal in the patients most likely to benefit remains untested. The company plans to initiate Phase 2a in higher BMI patients with comorbidities in Q2 2026.

Pipeline and Financial Backdrop

Wave carries a broader pipeline that may cushion sentiment over time. Wells Fargo noted that a clear dose response in the alpha-1 antitrypsin deficiency program could improve sentiment, with the firm viewing 9–10uM mutant alpha-1 antitrypsin at the 400mg multiple-ascending-dose as potentially achievable. Data from the RestorAATion-2 trial are expected in Q1 2026, with a late-breaking oral presentation at a major lung conference in May 2026.

Financially, the company reported FY 2025 revenue of $42.7 million and a net loss of $204.4 million, with cash of $602 million providing runway into Q3 2028. Despite the selloff, the analyst consensus target sits at $28.80 across 16 buy ratings and zero sell ratings — a gap that reflects how sharply the market has repriced execution risk.

What to Watch

The Phase 2a initiation in higher BMI patients is the next meaningful data inflection. WVE-007 must demonstrate efficacy in a population closer to the actual obesity treatment market before monotherapy conviction can build and the stock can recover toward pre-data levels.